Clinical
Trials
If you are a patient or health care provider who would like more information about a clinical trial, please contact our research team.
If you are a patient or health care provider who would like more information about a clinical trial, please contact our research team.
At BeiGene, we’re committed to bringing patients worldwide potential treatment options. We are currently recruiting clinical trials across areas including lymphoma, liver cancers, lung cancers, gastric cancers, breast cancers, and more.
-
BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors
Condition:
Advanced Solid Tumor
Molecule:Tislelizumab
-
AdvanTIG-203: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esopha…
Condition:
Esophageal Squamous Cell Carcinoma (ESCC)
Molecule:Tislelizumab + Ociperlimab
-
Study of the Safety and Pharmacokinetics of BGB-283 (Lifirfenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors
Condition:
Solid Tumor
Molecule:Lifirafenib
-
Tislelizumab Plus BGB-A1217 Versus Durvalumab When Co-administered With Concurrent Chemoradiotherapy (cCRT) in Lung Cancer
Condition:
Lung Cancer
Molecule:Tislelizumab
-
Study of BGB-11417 in Adult Participants With Mature B-cell Malignancies
Condition:
Mature B-cell Malignancies
Molecule:BGB-11417
-
Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma
Condition:
Lymphoma
Molecule:Tislelizumab
-
A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer
Condition:
Lung Cancer
Molecule:Tislelizumab + Ociperlimab
-
Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies
Condition:
B-cell Malignancies
Molecule:Zanubrutinib + Tislelizumab
-
Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab
Condition:
Leukemia, Lymphoma, Advanced Solid Tumor, Lung Cancer
Molecule:Zanubrutinib + Tislelizumab
-
Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment
Condition:
Lymphoma, Waldenström's Macroglobulinemia
Molecule:Zanubrutinib
Clinical trials are an important part of our research and development efforts and help make possible access to safe and potentially life-saving treatments.
This list includes trials with the following recruitment statuses: recruiting, enrolling by invitation, study start-up, not yet recruiting, and active/not recruiting.